LIFECORE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating LifeCore Biomedical, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against LifeCore Biomedical, Inc. due to a class action complaint alleging breaches of fiduciary duties by the company's board of directors during the specified class period [1][2]. Summary by Sections Investigation Details - The class action complaint was filed on July 29, 2024, covering a class period from October 7, 2020, to March 19, 2024 [1]. - Allegations include that LifeCore made materially false and misleading statements regarding its business operations and financial prospects [2]. - Specific claims include: 1. Deficient internal controls over financial reporting [2]. 2. Issuance of inaccurate financial statements requiring restatement [2]. 3. Ineffective remediation efforts regarding internal control deficiencies [2]. 4. Impaired ability to file periodic reports with the SEC, affecting NASDAQ compliance [2]. 5. Material overstatement of the company's financial position and prospects [2]. 6. Public statements being materially false and misleading throughout the class period [2]. Next Steps for Investors - Long-term stockholders of LifeCore are encouraged to contact Bragar Eagel & Squire for more information regarding their rights and the ongoing investigation [3]. - Contact options include email and telephone, with no cost or obligation for inquiries [3]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with a focus on representing individual and institutional investors in complex litigation [4]. - The firm operates in multiple states, including New York, South Carolina, and California [4].